Results 71 to 80 of about 70,073 (274)

Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives

Tumor Biology, 2017
Androgen receptor plays a pivotal role in prostate cancer progression, and androgen deprivation therapy to intercept androgen receptor signal pathway is an indispensable treatment for most advanced prostate cancer patients to delay cancer progression ...
Jieping Hu, Gongxian Wang, Ting Sun
doaj   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

Survival after spinal surgery for metastases in men with castration-sensitive vs castration-resistant prostate cancer: a nationwide register-based study

Scientific Reports
This nationwide register-based cohort study examined the association between castration status and postoperative survival in men who had undergone surgery for spinal metastases from prostate cancer. Bone metastases are common in prostate cancer, with the
Johan Wänman, Mehdy Farhang, Helena Nyström, Johan Styrke, Christel Häggström, Pär Stattin, Sead Crnalic   +6 more
doaj   +1 more source

Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer

Nature, 2014
Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease. Progression to CRPC after androgen ablation therapy is predominantly driven by deregulated androgen receptor (AR) signalling. Despite the success of
I. Asangani, Vijaya L. Dommeti, Xiaoju Wang, Rohit Malik, M. Cieslik, Rendong Yang, J. Escara-Wilke, K. Wilder-Romans, Sudheer Dhanireddy, Carl G. Engelke, Mathew K. Iyer, Xiaojun Jing, Yi-Mi Wu, Xuhong Cao, Zhaohui S. Qin, Shaomeng Wang, F. Feng, A. Chinnaiyan   +17 more
semanticscholar   +1 more source

Dynamic Profiling of Circulating Tumor Cells and MYC/PTEN Alterations in Prostate Cancer Patients Undergoing Radical Prostatectomy in Amazon Population

Molecular Carcinogenesis, EarlyView.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed malignancy among men and the sixth leading cause of cancer‐related mortality worldwide. Radical prostatectomy remains the standard treatment for localized disease; however, approximately one‐third of patients develop biochemical recurrence within 10 years. Although prostate‐specific
Juliana Ramos Chaves, Rommel Mario Rodriguez Burbano, Amanda de Nazaré Cohen‐Paes, Diego Di Felipe Ávila Alcântara, Ana Paula Borges de Souza, Maria Janete Nahum Gomes, Sérgio Augusto Antunes Ramos, André Salim Khayat   +7 more
wiley   +1 more source

Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages

Journal for ImmunoTherapy of Cancer, 2020
Background Previous studies of prostate cancer autoantibodies have largely focused on diagnostic applications. So far, there have been no reports attempting to more comprehensively profile the landscape of prostate cancer-associated antibodies ...
Jin Zhang, Douglas G McNeel, Tun Lee Ng, Hemanth K Potluri, Michael A Newton, Christopher A Maher, Peter S Nelson   +6 more
doaj   +1 more source

Evaluation of Loss of the Y Chromosome in Peripheral Blood as a Biomarker for Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Prostate cancer (PCa) is the most common malignant tumor in men, but the widely used prostate‐specific antigen (PSA) test has limited diagnostic accuracy. Research proposes that the loss of the Y chromosome (LOY) may affect the occurrence and development of prostate cancer, aiming to assess its potential as a diagnostic biomarker to
Jun Lu, Yan Lu, Takuro Kobayashi, Tsuyoshi Hachiya, Haruhiko Wakita, Yiming Jin, Yasunari Tanaka, Yoshihiro Ikehata, Masayoshi Nagata, Hisamitsu Ide, Shigeo Horie   +10 more
wiley   +1 more source

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation

The Prostate, EarlyView.
ABSTRACT Background Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).
Mayuko Kanayama, Violet A. Daniels, Marta Gielzak, Alex Brame, Misop Han, Li Jia, Jianfeng Xu, Tamara L. Lotan, Mario A. Eisenberger, Catherine H. Marshall, Patrick C. Walsh, William B. Isaacs, Jun Luo   +12 more
wiley   +1 more source

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2019
Most prostate cancers are androgen-sensitive malignancies whose growths depend on the transcriptional activity of the androgen receptor (AR). In the 1940s, Charles Huggins demonstrated that the surgical removal of testes in men can result in a dramatic ...
Qin Feng, Bin He, Bin He
doaj   +1 more source

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis

The Prostate, EarlyView.
ABSTRACT Background In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune ...
Tomoya Hatayama, Yohei Sekino, Go Kobayashi, Kazuma Yukihiro, Yoshinori Nakano, Shinsaku Tasaka, Naofumi Nomura, Yuki Kohada, Kenshiro Takemoto, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +16 more
wiley   +1 more source